This novel PRDX1‐TLR4‐ HIF‐1α pathway can be targeted by TLR4 inhibitors and can perhaps serve as a therapeutic target in the treatment of PRDX1‐driven prostate tumour angiogenesis. Here, TLR4 is linked to prostate neoplasm.